Lupin partners with Amman Pharmaceuticals Industries

10 Nov 2023 Evaluate

Lupin has partnered with Amman Pharmaceuticals Industries (Amman Pharma), a leading pharmaceutical manufacturer with operations across the MENA region and other global markets, for exclusive marketing and commercialization of Ranibizumab, a biosimilar of Lucentis, in the Middle East region, including select territories of Jordan, Saudi Arabia, UAE, Iraq, Lebanon and other GCC countries. Both Lupin and Amman Pharma are united in their mission to provide innovative, high-quality healthcare solutions to patients in the Middle East and North Africa (MENA) region.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2099.50 -12.50 (-0.59%)
01-Jan-2026 14:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.65
Dr. Reddys Lab 1250.90
Cipla 1499.55
Zydus Lifesciences 913.30
Lupin 2099.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×